Lakewood-amedex Biotherapeutics Inc. · NASDAQ:LABT
Lakewood-amedex Biotherapeutics — Investor Presentation (September 2026)
21 slides from Lakewood-amedex Biotherapeutics's investor presentation, Sep 25, 2026
Slide 1: Pioneering Bisphosphocin® Compounds
Pioneering Bisphosphocin® Compounds Advancing a novel class of fast- acting antimicrobials to address the global threat ofresistance 1
Slide 2: Forward-looking Statements
Forward-looki ng St at e me nt s T his p r es en ta ti o n m a y c o nt a in f o r w ar d - lo o k in g s t at e m e n t s a s d ef i ne d b y t h e Pr ivat e Se cu r itie s L iti gat io n Re f o r m A c t of 1995. Gen erally, t h e w o r d s "believe," "expect," "intends," "estimate," "anticipate,"
Slide 3: Antimicrobial Resistance (AMR): A Global Public Health Threat
A n t i m i c r o b i a l R e s i s t a n c e (AMR): A G l ob a l P u b l i c H e a l t h T h r e a t C o r e D ri ve rs o f A M R Dire ctl y cau se s 1.14 mil lion de ath s • W i d e s p r ea d u s e of s ys t em i c a ntib io tics annual l y a nd contri butes to nearl y 4 .7 mil lion de ath s worl
Slide 4: Value Proposition of Patented Bisphosphocin® Class
V al u e P r o p o s i t io n of P a t e n t e d B i s p h o s p h o c i n ® C l a s s First-in-clas s, a nt im ic ro b ia l c o m p o u n d s w i th p ot ent ial to m i ti ga t e t h e i m p a c t of t h e g lo b a l A M R cr is is B r o a d - s p ec t r u m act ivity a ga i n s t b o t h s u s ce
Slide 5: Bisphosphocin® — Proposed Mechanism of Action
B i s p h o s p h o c i n ® — P r o p o s e d M e c h a n i s m of A c t i o n Bisphosphocin ® c o m p o u n d s are novel, sm a ll n u cle o t id e de rivative s t h at are p ro p o se d to exert an tib acterial act iv it y b y t a rge t in g ba ct erial cell m e m b ra n e s , c a u s i n g rap id
Slide 6: Lead Program: Infected Diabetic Foot Ulcer (iDFU)
L e a d P r o g r a m : I n f e c t e d D i a b e t i c F o o t U lc e r (i D F U) G lo b a l P re va l e n c e • 8 30 M p eo p l e w i th diabetes ; (a) a b o u t o n e th ir d will d eve lo p a D F U ( b ) In fe c ti o n R a t e • ~5 0% of D F U s b e c o m e infected; m a n y p at ien t s fa c e
Slide 7: Nu-3 Selected for Clinical Development
N u - 3 S e l e c t e d for C l in i ca l D e v e l o p m e n t ( a ) B r o a d s p e c t r u m in vitro; N u - 3 s h o w n to b e ra pid ly cid a l a ga i n s t a b r o a d s p e c t r u m of m ic ro b es , i n c lu d in g res ista nt strains, w i th lo w p ot ent ial for r es ista n ce d e ve lo p
Slide 8: Nu-3 Demonstrates Rapid Bacterial Kill In Vitro
N u- 3 d em o n st r at e s r ap i d b ac te r i al ki l l i n v it r o ( a ) I n t i m e kill exp er im en t s, w h e r e b a c t e r i a a r e e x p o s e d to t h e B i s p h o s p h o c i n ® c l a s s of c o m p o u n d s , t h e a c ti o n is ra p id , w i th to ta l c ell d e a t h o c c u r
Slide 9: Nu-3 Gel Formulation Outperforms Solution Formulation
N u - 3 Gel Formulation Outperforms Solution Formulation (a) Nu-3 Solution vs Gel in Murine Dermal Infection Model 100 90 A t 1a n d 2 h o u r s p o st e st ab l is h e d in f ec t io n 80 1& 2 Infection as % of Control b o t h 10% g e l a n d 10% so l u tio n of N u - 3 H ours 70 s h o w >9 5 % in
Slide 10: Nu-3 Gel Active Either Once Or Twice Per Day
N u - 3 Gel active either once or twice per day in multidose study ( a ) 5-Day Multiple Dose Mouse Infection Model 100% 90% Infection as % of Conrtol 80% 70% A ft er 5 d a y s of t r e at me n t w i th 5 % N u - 3 g e l 5 % Ge l b o t h o n c e - a - d a y ( Q D ) a n d t w ic e - a - d a y ( B ID )
Slide 11: Advantages of Bisphosphocin® Class in Combating AMR
A d v a n t a g e s of B i s p h o s p h o c i n ® C l a s s i n C o m b a t i n g AMR : b a s e d o n av ail ab le n o n - c li n i c al e v i d e n c e R igh t D r u g R igh t Application R igh t MOA 11
Slide 12: Clinical Evidence Supporting Development of Nu-3
C l in i ca l E v i d e n c e S u p p o r t i n g D e v e l o p m e n t of N u - 3 P h a s e 1P a t c h St u dy • A 21‐D ay Re p e a t P a t c h Test to E va lu a te t h e Irr itatio n Po ten t ial of Test P r o d u c t (2% N u ‐ 3 in 0.85% Saline, W /V) o n A b r a d e d a n d I nta c t S k in Sit
Slide 13: Upcoming Phase 2a/2b Study Design With New Gel Formulation
U p c o m i n g P h a s e 2a/2b S t u d y D e s i g n w i th N e w G e l F o r m u l a t i o n S t ep O n e: P h a s e 2a S t u d y In d i c at i o n Nu-3 g el 2% N o t re at m e n t • In fec ted d ia b et ic foo t u lcer s SI NGL E B li nded , Nu-3 gel 5 % N o t re at m e n t S a fet y M ea s u res
Slide 14: iDFU Development and Regulatory Strategy
i D FU D e ve l opm ent a nd Regulat ory St ra teg y Geographic • P h a s e 2 U.S. d e v e l o p me n t Scop e • P h a s e 3 I n ter n ati o na l d e v e l o p me n t • 2 s ma ll ac c es s o r y s tu d i e s fu ll p h a r ma c o k in e t ic a n d s k in se n sit izat io n • E n d of P h a s e 2 M e
Slide 15: Development Pipeline
D e ve l opm ent Pipeline In di ca ti o n P ro g ram : D i s co v er y Pre- cl i ni c al Phase 1 Phase 2 Phase 3 St a t u s Ski n and Soft ti ssue Infe ct ions (SST I), N u -3 Ph a s e 2 ini tiation e.g., Infect ed D ia beti c Fo ot Ulc ers (iD FU) T ar g e ts : N u -8 • Pu l mo na r y Infec tions •
Slide 16: Upcoming Milestones
U p c o m i n g Mi l e s t o n e s 2Q26 • D r u g p ro d u ct m a nu f a ct u r in g i n it i at e d • S i t e e n ro l lm e n t in i t ia t e d 3Q26 • D r u g p ro d u ct m a nu f a ct u r in g co m p l e t e d • S i t e e n ro l lm e n t co m p le t e d • C l in i ca l T ri al C o mm e n c e s • F
Slide 17: Robust Intellectual Property Portfolio
R o b u s t In t el le ct ua l P r o p e r t y Po r tfo lio P a t e n t E xc l u s i vi t y 72 Is s u e d • K e y f ilin gs p ro vid e p ro te ct io n t h r o u g h 2 0 3 8 • Re c e n t a p pli ca tio n s ex t en d t h r o u g h 2 0 4 4 101 Pat e nt C ove ra ge P a te n ts • Pa t e n t s co ver c om
Slide 18: Nu-3 Well Positioned In Competitive Landscape
N u - 3 We ll Po s i ti o n e d i n Co m p e ti t i ve La n d sca p e O n l y On e D i rec t a n d C o m p a ra b l e C o m p et it o r – Re c c e’s R 3 27 Proprietary Topical • To p ica l a ge n t fo r Sk in & So f t T i ss u e I nfe ct io n s – fo cu s o n i D F U • La t e - st a ge d e v e l o p
Slide 19: Experienced Management With Industry Depth
Expe ri e nce d M an a g e m e nt with Industry D e pt h L ea d e rsh ip B o ard D o u g M a ni o n, M.D., F R C P ( C ) C h a i r ma n Le on ard J. D e R o m a K e l v i n C o o p e r, P h . D. P e te r C e c c a c c i T h o m a s B a lz e r, M.D., P h . D. Direc tor C hief Exe cu ti ve Of fic er C
Slide 20: Pioneering Innovations to Combat Drug-Resistant Infections
P i o n e e r i n g I n n o v at i o n s to C o m b a t D r u g - R e s i s t a n t I n fe c t i o n s Cl i ni c al- s tage bi o te c hnol o gy c o m p a n y de v e l op i ng a novel class of fast-acting, broad-spectrum antimicrobials — B i s ph os ph oc i n ® c o m p o u nd s — to t reat i nfect i
Slide 21: BIOTHERAPEUTICS
BIOTHERAPEUTICS medex Lakewood co e
Lakewood-Amedex Biotherapeutics — Investor Presentation (September 2026) on 6ix